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Alpha-mannosidosis is a rare autosomal recessive lysosomal-storage disorder resulting 
from deficiency of lysosomal alpha-mannosidase activity. The disease shows a wide 
range of clinical phenotypes caused by intracellular accumulation of mannose-
containing oligosaccharides, which ultimately may lead to mental retardation, hearing 
loss, skeletal changes and immune deficiency. Lysosomal alpha-mannosidase is a 
hydrolase that cleaves alpha-linked mannose residues from the non-reducing end of N-
linked glycans of glycoproteins. So far, 40 alpha-mannosidosis associatied sequences 
have been reported, but no correlation of clinical and disease associated sequence 
variations has been detected so far. In previous work, seven of alpha-mannosidosis 
sequence variants were identified. Missense mutation p.H200L was previously reported 
as alpha-mannosidosis associated mutation (Sbaragli et al., 2005). 
This study was undertaken as part of the functional characterization of mutant alpha-
mannosidase. The mutations were introduced into an expression vector containing the 
wild-type LAMAN cDNA by in vitro mutagenesis, and the resulting proteins were 
expressed in COS-7 and BHK cells. Mutants p.C55F and p.R750W showed activity less 
than  8% of wild-type. The mutants were misfolded in the ER as  inactive single-chain 
form and contained endo H sensitive N-glycans. The mutant p.P263L showed 8-10% of 
normal activity, whereas p.S318L, p.S453P, p.V457E and p.T745R expressed high 
residual activity (18-34%). They were processed into peptides abc and d which 
contained  both high mannose and complex N-glycans, suggesting that a fraction of 
these mutants were transported to the lysosomes. The mutant p.T745R precursor 
contained only endo H sensitive glycans. It was proteolytically processed into the abc 
and d peptide but was not secreted into the medium. The mutant p.C55F was transport-
arrested and accumulated in the endoplasmic reticulum (ER). In contrast, the mutant 
p.H200L, p.P263L, p.S.318L, p.S453F, p.V457E and p.T745R allowed a small fraction 









aa      amino acids 
amp     ampicillin 
BHK     Baby hamster kidney 
BSA     Bovine serum albumin 
cDNA     complementary DNA 
CHO     Chinese hamster ovary 
COS-7     African green monkey kidney cells 
DMEM    Dulbecco’s modified Eagle’s Medium  
DNA     deoxyribonucleic acid 
EDTA     Ethylene Diamine Tetraacetic Acid 
ER     endoplasmic reticulum 
ERT     Enzyme replacement therapy 
FBS     Fetal bovine Serum 
GlcNac    N-acetylglucosamine 
Kb     kilo base 
kDa     kilo Dalton 
LAMAN    Lysosomal alpha mannosidase 
LAMP 1    Lysosomal-associated membrane protein 1 
LSD     Lysosomal Storage Disease 
Man     Mannose 
Man-6-P    Mannose-6-phosphate 
MEM     Minimum essential medium  
Met     Methionine 
OD     optical density 
PBS     Phosphate-buffered saline 
PDI     Protein disulfide isomerase 
PCR     Polymerase chain reaction 
rpm     revolution per minutes 
RT     Room temperature 
TGN     Trans Golgi network 





 Glycoproteins are  proteins that have oligosaccharide chains covalently attached to 
their polypeptide side-chains (reviewed in Varki, 1993). The oligosaccharide chains are 
added to the proteins during the cotranslational or posttranslational modification 
process  known as glycosylation. The glycoproteins are synthesized by the attachement  
of sugar chains to the amide nitrogen on the side chain  of asparagine (N-glycosylation) 
or to the hydroxyl oxygen on the side chain of hydroxylysine, hydroxyproline, serine, 
or threonine (O-glycosylation)(reviewed in Helenius and Aebi, 2001). The N-linked 
glycans play important functions such as promoting protein folding, quality control, 
intracellular sorting and transport to the proteins final destination (Helenius and Aebi, 
2001). Ultimately, the glycans are degraded in the lysosomes by a group of 
exoglycosidases acting at the nonreducing termini, and by endo-ß-N-
acetylglycosaminidase and aspartylglycosaminidase at the reducing end (Aronson et al., 
1989). Specific deficiences of these enzymes result in oligosaccharide accumulation  
that cause  lysosomal storage diseases such as alpha-Mannosidosis, ß-Mannosidosis, 
Fucosidosis and Sialidosis (Winchester et al., 2000). 
 
Figure 1 The biosynthesis of N-linked oligosaccharides. A block of 14 sugars is added 
to the newly synthesized polypeptide in the ER. The N-glycan is subjected to extensive 
modification as the glycoprotein move through ER and Golgi  (Walsh et al., 2006). 
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Most glycoconjugates are degraded in the lysosomes, and a portion of the liberated 
monosaccharides are reused for glycoprotein synthesis (Freeze ,1999) . The breakdown 
of N-glycans from glycoproteins and glycopeptides is ordered and highly specific ( 
Figure 2).  
 
 
Figure 2 Lysosomal degradation of complex N-linked glycoproteins. The figure 
shows two sets of reactions (1-6 and I-IV) occuring idenpendently of each other. In 
reaction 1-6, exoglycosidases act stepwise in the removal of oligosaccharides from the 
non-reducing end. In reaction I-IV the protein and the protein-to-carbohydrate linkage 










Lysosomes and lysosomal enzymes 
 Lysosomes are intracellular organelles required for the final digestion of 
macromolecules such as  proteins, lipids, carbohydrates and nucleic acids (Varki, 1999) 
The degradation of macromolecules is carried out by the action of at least 60 distinct 
hydrolytic enzymes, including proteases, nucleases, lipases, sulphatases, phosphatases 
and glycosidases (Mader, 2007). Most of these enzymes have been characterized and 
are active at low pH (de Duve et al., 1995). The lysosomal enzymes are synthesized on 
the ER membrane and follow the initial route of the secretion pathway (Figure 3).  
 
Figure 3 intracellular targeting of lysosomal (pink) and secretory (blue ) proteins. 
The lysosomal protein follows the M-6-P pathway, while the secretory protein does not 
acquire the M-6-P-marker and is thus secreted (from Lodish et al., 1999).  
 
 
The synthesis is initiated by the translation of a signal sequence, which is recognised by 
a signal recognition particle (SRP). Interaction with the SRP results in the translocation 
of the polypeptide into the lumen of the ER. In the ER, the protein is N-glycosylated by 
the oligosaccharide-transferase complex which transfers the oligosaccharide precursor 
to the consensus sequence Asn-X-Ser/Thr (where X is any amino acid except proline) 
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of a nascent chain polypeptide (Silberstein and Gilmore 1996). Following a series of 
trimming reactions of the N-glycans, the lysosomal proteins are properly folded and 
transported to the cis-Golgi for addition of the mannose-6-phosphate marker (M-6-P). 
This process involves two enzymatic steps (Waheed et al., 1981). In the first step, the 
enzyme UDP-N-acetylglucosamine 1- phosphotransferase recognizes and transfers a 
alpha-N-acetylglucosamine 1-phosphate residue to the 6-position of a mannose on a 
high-mannose oligosaccharide as the protein is transported from the ER to the Golgi 
apparatus (Sousa and Parodi, 1995). In the second step, the N-acetylglucosamine 
residue is trimmed from the oligossacharide chains by a glucosidase (N-
acetylglucosamine 1-phosphodiester-N-acetylglucosaminidase) exposing it for 
recognition and uptake by the mannose 6-phospate receptor  (Varki et al., 1983). After 
reaching the trans-golgi network (TGN), the phosphorylated mannose residues bind to 
the receptor, which direct the packing into  transport vesicles. The lysosomal protein is 
recognised by two independent M-6-P receptors with different specificity that direct 
their transfer to lysosomes. After binding of the enzymes to the receptors, the 
complexes are incorporated into clathrin-coated vesicles that bud off from the trans-
Golgi network and fuse with acidic prelysosomal compartments termed endosomes. 
The low pH dissociates the lysosomal enzyme from the M-6-P receptor, and 
phosphatases remove the phosphate from the lysosomal enzyme to prevent  rebinding 
to the receptor. The receptors are then returned to the Golgi complex for reultilization, 
while the lysosomal enzymes enter the lysosomes through fusion between endosomes 
and lysosomes (see Schmid et al., 1997). 
 
Secretion of lysosomal enzymes 
Many cell types secrete lysosomal enzymes. The enzymes are secreted  either  as higher 
molecular weight precursors or as proteolytically processed mature forms (Jessyp et al., 
1985). In mammalian cells, secretion of the lysosomal enzymes may be result of the 
absence of specific targeting signals (Reitman et al., 1981), or defective or absence of  
receptors (Robbins and Myerowitz et al., 1981). In this case the lysosomal enzymes 
never home to the lysosomes  and are instead secreted directly from the Golgi (Figure 
3). Secretion of lysosomal proteins in high-producer cells , may be caused by saturation 




 Lysosomal alpha-mannosidase (MAN2B1; EC 3.2.1.24) is a member of the 
Glycosyl Hydrolase family 38 (Henrissat and Bairoch, 1996). It is an acidic 
exoglycosidase, which cleaves alpha-linked mannose residues from the nonreducing 
end of N-linked glycoproteins (al Daher et al., 1992; DeGasperi et al., 1991) during the 
ordered degradation of N-linked oligosaccharides . In addition to the cleavage of the 
natural substrates, the enzyme is also specific for the synthetic substrates, p-
nitrophenyl- alpha-D-mannopyranoside and 4-methylumbelliferyl alpha-D-
mannopyranoside (DeGaseri et al., 1991). The three-dimensional structure of two 
GH38 enzymes, Golgi alpha-mannosidase II from Drosophila melanogaster (Elsen et 
al., 2000) and LAMAN from bovine kidney have been solved (Heikinheimo et al., 
2003). 
 The human LAMAN has been purified from various tissues. The human placenta 
LAMAN is synthesized as a polypeptide of 1011 amino acids (Nilssen et al., 1997). 
The enzyme is post-translationally modified by N-glycosylation, disulphide bridge 
formation, proteolysis and zinc binding (Nilssen et a.l, 1997). The enzyme is 
synthesized as a precursor that is active in various cell types (Thomas and Beudet , 
2001) and processed into three glycopeptides of 70, 42 and 15 kDa (Nilssen et al, 
1997), the 70 kDa peptide abc is further processes in bovine kidney (Tollerud et al., 
1997), but this peptide is only partially processed in the human enzyme (Nilssen et al., 
1997) 
The human and bovine LAMAN contain 11 and 8 potential N-glycosylation sites, 
respectively. Most N-glycosylation sites of the human LAMAN enzyme are occupied 
by high mannose and complex type N-linked oligosaccharides (Nilsen et al., 1997). In 
addition, the bovine LAMAN also contains hybrid-type glycans (Tollersrud et al., 
1997; Faid et al., 2006). The p.N497 glycosylation site is evolutionary conserved 
among LAMANs, and it may be important for the stability of the enzyme. Both the 
secreted and the lysosomal forms contain endoglucosidase H complex type glycans 




Figure 4. Human placenta LAMAN. The LAMAN peptides are labelled with a, b, c, 
d and e . The black filled box shows the signal peptide. The amino acid numbers under 
the diagram indicate the cleavage site positions. The 11 N-glycosylation sites are shown 
as “lollipops” above the diagram. Open circles indicate high mannose type 
oligosscharides whereas filled circles indicated complex type oligossacharides. The 
type of oligossacharides linked to the e-peptide is still unknown (Nilssen et al., 1997). 
 
 
The gene encoding lysosomal alpha-mannosidase (Genbank accession no. U60266.1) 
has been localized close to the centromere of chromosome 19 (19p13.2) (Gonzalez et 
al., 1999). The gene spans approximately 22 kb and consists of 24 exons. The LAMAN 
transcript is about 3,5 kb and contains an open reading frame encoding 1011 amino 
acids with two potential initiation sites for translation (Nilssen et al., 1997). The 5’ 
flanking region of the gene does not contain TATA or CAAT boxes, but several GC 
rich regions and putative biding sites for the transcription factor Sp1 have been 
identified. Multiple transcription start sites have been identified at posistion -191,-196 
and -309 and at position  -28 and -20 ( Riise et al., 1997). The exons 2-14 encode 
polypeptide “abc”, whereas peptide “d” is mainly encoded by exons 15-21, and the 
smallest polypeptide “ e” is encoded by exons 22-24.  
 
Lysosomal storage disorders 
Lysosomal storage disorders (LSD) are inherited metabolic disorders that result from 
defects in lysosomal function (see table 1).There are more than 45 different diseases 
caused by defect of lysosomal degradation of macromolecules (Neufeld, 1991; 
Gieselmann, 1995). Gaucher disease was the first of these disorders to be described, in 
1882, followed by Fabry disease in 1898 (Winchester et al., 2000). Most of these 
disorders are autosomal recessively inherited, however a few are X-linked recessively 
inherited, such as Fabry disease and Hunter syndrome. The general feature of these 
diseases is the accumulation of undigested products that result in disruption of the 
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normal function of lysosomes, and eventually leading to cell death (Beutler et al., 
2001). Accumulation of the undigested products are mainly caused by deficiency of the 
hydrolytic enzymes. The LSDs show a wide spectrum of clinical phenotypes. The 
severity of a given LSD depends partially on the type of storage material product and 
on which cells or tissues that accumulate the storage material. However, genetic 
background and other factors also influence the disease outcome. 
 
Table 1  Examples of major groups of Lysosomal storage diseases. 
 
Disease (s)   Enzyme defect  Accumulated material 
 
Sphingolipidosis GM 1 Beta-galactosidase  GM1 ganglioside 
Tay-Sachs disease GM2  Hexosaminidase A  GM2 gangliosides 
Sandhoff’s disease GM2   Hexosaminidase A   GM2 gangliosidosis 
Krabbe’s disease   Galactosyl ceramid beta- Galatocerebrosides 
Nieman-pick disease, type Sphiingomyelinase  Sphingomyelin  
Gaucher’s disease   beta-glucocerebrosidase Glucosylceramide 
Fabry’s disease   alpha-Galactosidase A Glucosyceriamide 
Glycoprotein storage  alpha-Fucosidase  Trihexosylceramide 





 Alpha-mannosidosis (MIM 248500) is an rare autosomal recessive lysosomal-
storage disorder caused by the deficiency of LAMAN (Thomas and Beaudet 1995). The 
disease has been characterized in man (Ockermann, 1967), cattle (Hocking et al.1972; 
Healy et al., 1990), cats (Burditt et al., 1980; Cumming et al., 1988) and guinea pigs 
(Crawley et al.,1999). Carrier parents have a risk of having an affected child of 25 
percent. A prevalence is of about 1:500000. Typical clinical symptoms are coarse facial 
features, mental retardation, variable hepatosplenomegaly, hearing loss, and dysostois 
muliplex (Thomas and Beaudet, 1995). Alpha-mannosidosis shows a wide range of 
clinical phenotypes with varying degrees of severity. The variation in clinical 
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phenotype is not only caused by lack of enzyme activity, it may be due to both 
environmental factors and genetic factors. Lacking of enzyme activity found in patients 
who have different clinical phenotypes (Berg et al., 1997). The clinical diagnosis of 
alpha-mannosidosis is based on detection of mannose-rich oligosaccharides, and direct 
measurements of alpha-mannosidase activity in various cell types, such as leukocytes, 
fibroblasts, and amniocytes (Chester et al., 1982; Thomas and Beaudet,1995 ). 
 So far, more than 110 alpha-mannosidosis-associated sequence variants have been 
detected in over 170 unrelated patients (Riise Stensland et al., manuscript in 
preparation). Forty alpha-mannosidosis-associated sequence variants have been 
reported in litteratures (Nilssen et al., 1997; Gotoda et al., 1998; Berg et al., 1999; 
Becarri et al., 2003; Olmez et al., 2004; Urushihara et al., 2004; Sbaragli et al., 2005; 
Castelnovo et al., 2007; Lyons et al., 2007; Pittis et al., 2007;). Most of  alpha-
mannosidosis-associated sequence variants occur in one or a few families, but the 
specific sequence variant mutation c.2248C>T (p.R750W) appears to account for a 
large fraction of  alpha-mannosidosis disease alleles. The mutation was identified in 13 
patients from different European countries (Berg et al., 1999). There is no clear 
correlation between clinical phenotype and disease-associated sequence variants, and 
disease-causing variants are responsible for the inactivation of LAMAN by misfolding 
and mislocation of the LAMAN enzyme or by active site distortion (Hansen et al., 
2004). Mutant LAMAN enzyme may be mislocalized to nonlysosomal compartments, 
even though containing residual activity upon testing at the appropiate pH (Nilssen et 
al., 1997). Therefore, to establish the relationship between genotype and phenotype 
suggested, the enzyme activity should be measured on fractionated lysosomes. 
 
There is no effective therapy for alpha-mannosidosis, but when the  purified active 
enzyme was added to the medium of mannosidase-deficient fibroblasts, the 
accumulation of lysosomal storage products was corrected (Abraham et al, 1985). ERT 
have been performed on alpha-mannosidosis mouse, the result showed to decrease in 
mannose-containing oligosaccharides in tissues, including brain (Roces et al., 2004). 
Therefore, it is possible that ERT could be used to treat alpha-mannosidosis in humans 
in the future. The lysosomal vacuoles in alpha mannosidosis guinea pigs decreased 
markedly in liver, kidney, spleen, pancreas and trigeminal ganglion neurons (Crawley 
et al., 2006), but in a guinea-pig model, no histologic changes were seen in the brain. 
ERT has not been tested on human. Bone-marrow transplantations (BMTs) have been 
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performed in alpha-mannosidosis with varying outcomes. Early BMT attempts were 
unsuccessful in one child (Will et al., 1987) and successful in another (Wall et al., 
1998). The donors are not available for the majority of alpha-mannosidosis patients. 
BMT had been  performed in feline alpha-mannosidosis, where BMT has led to 
replacement of alpha-mannosidosis activity in cells of the central nervous system 



























Aims of this study 
In previous work (Nguyen, 2008 and Stensland et al., manuscript in preparation), the 
alpha-mannosidosis associated sequence variants, p.C55F, p.H200L, p.P263L, 
p.S318L, p.S453F, p.S457E and p.T745R in the LAMAN gene were identified. The 
mutant, p.H200L had been suggested to be disease-associated based on activity 
measurements and modelling into the three dimensional structure, but the consequences 
on intracellular processing and localization were not investigated. 
 
This study was undertaken to characterize these sequence variants at the biochemical 
and cellular level to study their effect on the LAMAN protein and to investigate if they 
are disease-causing mutations. 
Specific goals were: 
 - Enzyme activity analysis of mutant LAMANs  





















Subjects and Methods 
 
Subjects 
In a previous work (Nguyen 2008), putative alpha-mannosidosis associated sequence 
variants were detected in the patient from three unrelated families from Grea Britain , 
Italy and Chile. Four other putative disease-associated sequence variants were detected 
in four unrelated patients  from Turkey, Great Britain and Germany, respectively (Riise 
Stensland et al., manuscript in preparation) (See table 2). All patients were diagnosed 
with alpha-mannosidosis by enzyme assays/thin layer chromatography at the referring 
center , and DNA and/or blood samples from patients and family members were 
provided by their physicians. The study was a part of the HUE-MAN project and 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































The cDNA encoding the human LAMAN contained in the expression vector pcDNA 
3.1 (Hansen et al, 2004) served as template for site-directed mutagenesis using the 
QuickChangeTM Site-Directed Mutagenesis Kit (Stratagene), and the primers were 
used are listed in the table A (see additional materials). The amplification was 
performed for 19 cycles. Each cycle consisted of 50 seconds denaturation at 95oC, 50 
seconds annealing at 60 oC, and 7 minutes extension at 68 oC. After PCR amplifcation, 
the reactions were placed on ice for 2 minutes to cool the reaction to ≤37°C. 1 µl of the 
Dpn I restriction enzyme (10 U/µl) added directly to each reactions and gently 
thoroughly mixed centrifuged for 1 minute and then immediately incubate at 37°C for 1 
hour to digest the parental (i.e., the nonmutated) supercoiled dsDNA. 
 
Transformation and culturing of bacterial cells 
XL-10 Gold Ultra supercompetent cells (Stratagene) were transformed with the 
mutagenesis-mix as recomanded by the manual instruction. The 45 µl of 
supercompetent cells were added to 2µl of mutagenesis-mix and incubated on ice for 30 
minutes, heat-shock for 45 seconds at 42 oC and immediately placed on ice. Cells were 
added 500 µl of  SOC medium and incubated at 37 oC for 1 hour with shaking, plated 
on LA-plates containing 100 µg/ml ampicillin, and incubated at 37 oC overnight. 
Five colonies from each plate were dispersed in 4 ml LB medium containing 100 µg/ml 
ampicillin to make over-night cultures and streaked separately on new amp plates to 
check for false positive colonies.  
 
Plasmid purification 
The plasmids from the 4 ml cultures or 60 ml overnight cultures were purified using 
Mini/Midi-preps DNA Kit (QIAGEN) according to manual instruction. The plasmid 
DNA was eluted and dissolved in sterile water. The plasmid concentrations were 






DNA sequencing  
The presence of mutation was verified by DNA sequencing (Bigdye 3.1 ABI). The 
LAMAN insert was sequenced for each mutant to ensure that no other mutation had 
been introduced by the PCR-based mutagenesis procedure. The sequencing reaction 
was run using the condition given in table 3. The primers 263R, 30F, 262F, 304bF, 
305bF and 306bF were used to sequence the insert ( see Riise et al., 1997). 
 
Table 3 Cycling parameters for sequencing reactions 
 
Cycle number Parameter  Temperatur ( 
oC) time 
 
25   Denaturation  95    0 seconds 
   Annealing  50    5   seconds 
   Extension  60   4   minutes 




Transfection of COS-7 , BHK-21 and CHO-K1 cells 
COS-7, BHK-21 and CHO-K1 cells (CRL-1651; American Type Culture Collection) 
were cultured and maintained in DMEM (Dulbecco’s modified Eagle’s ,medium) 
(Gibco, Invitrogen), whereas BHK cells were maintained in MEM (minium essential 
Eagle’s medium) (Gibco, Invitrogen) supplemented with 10 % FBS (foetal bovine 
serum) and antibiotics (penicillin and streptomycin) at 37 oC in 5% CO2 incubator. For 
transfection, the cells were seeded in 6-wells plates at a density of 3.0 x 106 cells with 2 
ml medium per well 1  day before transfection. The next day, cells were transfected 
with 2 µg of respective plasmid DNA diluted into 250 µl OPTI-MEM I  Reduced 
Serum Medium (Invitrogen Life Technologies). The plasmid DNAs were added to a 
mix containing LipofectAMINETM 2000 (Invitrogen) diluted in reagent 250 µl OPTI-
MEM reagent and incubated at RT for 20 minutes . After incubation, the medium was 
replaced by the fresh medium and added the plasmid-mix to each well. Cells were 
incubated for 12, 24, 36 and 48 hours. Each construct was transfected in duplicate for at 
least two independent experiments. 
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Enzyme activity analysis and protein concentration measurement. 
The media from each well was removed for further analysis, were washed  2x with PBS 
and lysed in 250 µl MPER- extract reagent (Thermo Scientific) and protease inhibitor 
mixture (Roche Biochemicals). The mediasand cell lysates were centrifuged at 13000 
rpm for 5 minutes, and the supernatants were transferred to  new tubes. Enzymic 
activity was measured  in the cell lysate and media by incubation with 4 mM p-
nitrophenyl alpha-D-mannoyranoside, (pH 4.7)(Sigma) for 1 hour at 37 oC. The 
reaction was stopped by the addition of an equal volume of stopp-solution contained 13 
mM glycine, 67 mM NaCl, and 83 mM Na2CO3 (pH 10.7). The absorbance was 
recorded at 405 nm; 1 unit of enzymic activity was defined as the amount of enzyme 
that liberated 1 µlmol of p-nitrophenol/min. The protein concentration was measured by 
the Dc-protein assay kit (Bio-Rad) as described by the supplier. The absorbances were 
recorded at 750nm (Microplate Reader with Softmaxr, biocompare). The enzyme 
activity and protein concentration measurement were performed in triplicate.  
 
Western blot 
Ten µg of protein and 10 µl of medium were added 2.5 µl of 5% SDS and 1.25 µl 
reducing agent (Invitrogen) and boiled at 100 oC for 10 minutes to denature the protein. 
After boiling, the samples, protein standard marker (Invitrogen) and Seeblue2 
(Invitrogen) were centrifuged at 13000 rpm for 5 minutes and loaded to an 4-12% 
gradient gel for protein separation by SDS-PAGE. The gel was run for 60 minutes and 
blotted to PDVF membrane (Invitrogen) by electro-blotting. After 1.5 hour blotting, the 
membrane was washed in PBS. The membrane was incubated blocking solution (150 µl 
Tween, 7.5 g drymilk, 150 ml PBS). The membrane was incubated in blocking solution 
with 2 µl antibody (Zymenex provided by Denmark) against denaturated recombinant 
LAMAN diluted 1:7500 over night at 4 oC . The membrane was washed 3 times with  
PBST (0,1 % Tween (Sigma) in PBS) for 5 minutes, and then incubated in secondary 
antibody (Alkaline phosphatase-conjugated chicken-anti-rabbit IgG diluted 
1:2000)(Santa Cruz Biotechnology) for 1 hour, and washed 4 times with PBST for 5 
minutes. 3 ml of the CDP-star substrate (Roche Biochemicals) was added to the 
membrane and incubated in dark for 30 minutes. Finally, the immunocomplexes were 




For in vitro studies of the glycan structure of glycoproteins, two different enzymes are 
usually used. Endoglycosidase H (endo H) is specific to high-mannose N-glycans. It 
digests within the chiobiose core and leaving one GlcNAc residue attached to the 
asparagines of the N-glycosylation sites (Figure 5). The second enzyme that has ability 
to cleavage the linkage between GlcNAC and asparagine to release N-linke glycans 
from glycopeptides called Peptide-N-glycan asparagine amidase F (PNGase F). Its 
enzymatic cleavage site is highly specific, with highly specific hydrolysis occuring 
between asparagine and GlcNAc of most high-mannose and complex type N-glycans. 
This liberates the oligosaccharide from the asparagine of glycosylation sites (Figure 5) 
 
Figure 5. Lysosomal degradation of complex N-linked glycoproteins. Endo H cleaves 
within GlcNAc-GlcNAc while PNGase F between asparagine and the asparagine and 
the GlcNAc (Maley et al., 1989) 
 
In order to study the type and structure of glycan attached to the LAMAN, the protein 
lysates were treated with Endo H (EC 3.2.1.96) and PNGase F(EC 3.5.1.52) (New 
England Biolabs). Generally 10 µg of cell lysates was added to a reaction sample of 10 
µl contained 10x glycoprotein denaturate and H2O. The reaction sample was heated for 
10 min at 100 oC. For Endo H treatment, the heated sample was added 2 µl of 10x G5 
reaction buffer (endo H buffer) , 3  µl of 500U/ml Endo H and H2O to a total reaction 
volume of 20 µl. For PNGase F treatment, the sample was added 2 µl 10x G7 reaction 
buffer (PNGase F buffer), 2 µl of 10 % Nonidet P40, 1.5 µl PNGase F and H2O to a 
reaction volume of 20 µl. The samples were incubated for 2 hours at 37 oC, added 5 µl 
of SDS and 2,5 µl  reducing agent and boiled for 10 minutes at 100 oC. The samples 
were centrifuged, and supernatant was applied to an 4-12 % gradient SDS/PAGE gel 




COS-7  and BHK-21 cells were plated at a density of: 2 x 105 cells/well on coverslips 
in 6-well culture plates (4 coverslips per well) 1 day before transfection. The 
pcDNA3.1 containing wildtype lysosomal alpha-mannosidase construct was used as 
positive control and vector pcDNA3.1 lacking lysosomal alpha-mannosidase (mock 
construct) was used as negative control. Transfections were performed using 2.0 µg of 
plasmid DNA as described above. 
After 40- 48 hours, cells were washed with 1x 2 ml PBS and 1x 1 ml serum free 
DMEM. Protein synthesis was stopped by incubation in 1 ml serum-free DMEM with 
50µg/ml cyclohexamide (Sigma) and incubated for 2-3 hours at 37 oC. Cells were 
washed with 3x 2ml PBS, fixed in 1 ml ice-cold methanol by incubation for 6 minutes 
at -20 oC, followed by 2x PBS wash, incubated coverslips in blocking solution (0.5% 
BSA, 0.2 % saponin (Sigma) for 45 minutes at RT to block unspecific staining. 
Coverslips were dried on paper and transferred to 24-well plates  and incubated for 45 
min at RT in primary antibody diluted in blocking solution (40 µl primary antibody 
solution per coverslip). The following antibodies were used   
-rabbit-anti-LAMAN denature bovine (1: 500 dilution) (Tollersrud et al., 1997) 
-Mouse-anti-LAMP1 (H3A4, lysosomal marker, 1:200 dilution) (Thomas August, 
John Hopkins University , Baltimore, MD, USA) 
-Mouse-anti-PDI ( ER marker , 1:200 dilution) (Stressgen) 
Cells were washed in 3 x 0.5 ml blocking solution and incubated with 40 µl of 
secondary antibody (molecular probes Alexa-488 goat-anti-rabbit IgG (Invitrogen) and 
Alexa-555 goat-anti-mouse IgG (Invitrogen) 1:500 dilution) for 45 minutes at RT. 
After washing with 3 x 0.5 ml PBS, the coverslips were dried and mounted upside-
down in a drop of glycerol. The cells were examined by FISH microscope using two 
different filter sets: The “green“ called FITC (Fluorescein isothiocyanate) and the “red“ 
called TRITC (Tetramethylrhodamine 5-isothiocyanate). The cells were visualized and 








Optimization of transfection of COS-7, BHK-21 and CHO-k1 cells 
The optimal growth time transfection conditions were established for COS-7 , BHK-21 
and CHO-k1 cells  using wild-type LAMAN and mock constructs. The cell lysates and 
medias were harvested after 12, 24, 36 and 48 hours post transfection, and enzyme 
activity, protein concentration measurement and Western blot analysis were performed. 
In COS-7 cells, the LAMAN activity was highest at 48 hours (20 fold higher than 
mock/background). In BHK the activity was 19 times higher than mock-transfected 
cells at 24 and 48 hours. Whereas, CHO cells produced highest alpha-mannosidase 
activity at 36 hours, but it was only 7x fold higher than in mock transfected cells. 
(Table 5 and figure 6) 
 
Table 5 alpha-mannosidase activities in transfected CHO-k1, BHK and COS-7 
cells. 
Cell lines    Enzyme activity * (fold increase) 
   12 h   24h   36h  48h 
CHO-k1  2   5   7  4 
BHK-21  4   19   15  19 
COS-7  2   7   7  20 
 







Figure 6 alpha-Mannosidase activities in cell-lysates 
COS-7, BHK-21 and CHO-k1 cells were transfected with pcDNA3.1-LAMAN and 
mock- construct, and lysates were harvested after 12, 24, 36 and 48 h post transfection. 
Alpha-mannosidase activity is adjusted. 
 
 
Western blot analyses showed that the processing of LAMAN in transfected COS-7 and 
BHK-21 cells is detectable after 24 hours, where proteolytically processing of the 120 
kDa single-chain precursor into peptides abc, d and e is observed with highest band 
intensity after 48 hours (Figure 7). Secretion of the 120 kDa single-chain precursor into 
the media after highest at 48 hours. In transfected CHO cells, a slow proteolysis of 
LAMAN into peptides abc and d, with highest intensity after 36 hours. The 
extracellular form had reached the peak levels after 36 hours. Together the results of 
enzyme activity and western blot indicate that transfection incubation time for COS-7  
BHK-21  cells should be at 36-48 hours, and 36 hours for CHO cells. The CHO cells 
were not used further due to the low expression of alpha-mannosiddase (7 fold) and 









A) Cell lysate 






B) Cell Media 
COS-7     BHK    CHO-k1 
 
 
          
Figure 7  Western-blot analyses of wild-type (WT) human LAMAN  
Ten µg of (COS-7 BHK), 20 µg  of CHO protein lysates and 10 µl media from three 
cell lines transfected with wildtype LAMAN and mock were subjected to Western blot 
analysis using  the primary antibody against denatured human LAMAN Molecular 





Alpha-mannosidase activity of mutant LAMANs in transfected COS-7 
and BHK-21 cells 
To establish whether the mutations p.C55F, p.H200L, p.P263L, p.S318L, p.S453F, 
p.V457E ,p.T745R, constructs affect alpha-mannosidase activity, we transiently 
expressed these mutant in COS-7 and BHK-21 Cells. The construct contained p.R750W 
was used as a negative controll as it shows no activity in transfected COS-7 cells 
(Hansen et al., 2004) Expression of the pcDNA3.1-p.H200L, p.S318L, p.S453F, 
p.V457E and p.T745R in COS-7 cells produced alpha-mannosidase activity  that was 4-
8 fold higher than that in mock-transfected cells (Figure 8 b). In BHK transfected cells 
alpha-mannosidase activity  was 2-6  fold higher in mutant compared mock-transfected 
cells, respectively (figure 8 d). The activity of p.C55F, p.P263L and p.R750W showed 
no signficant increase over background levels (Figure 8). The LAMAN activity in 
media was higher than the intracellular level. Activity of mutant LAMANs (p.H200L, 
p.S318L, p.S453F, p.V453E) are about 2 fold higher than p.P263L in media (Figure 9), 












Figure 8 Alpha-mannosidase activities in transfected COS-7 and BHK-21 cells. COS-7 
and BHK-21 transfected with 2µg control plasmid or plasmid containing mutant 











Processing of mutant LAMANs  in transfected COS-7 and BHK-21 
cells 
In order to study intracellular processing of  different LAMAN-variants, COS-7 and 
BHK cells were transfected with the 7 mutant pcDNA3.1-LAMAN constructs as well 
as p.R750W was used a a negative control of processing (Hansen et al., 2004). The 
lysates and mediums were harvested from transfected cells and subjected to Western 
blot analysis using LAMAN antibodies raised against human LAMAN (Figure 9). The 
LAMAN 120 kDa band, corresponding to the precursor abcde form of LAMAN, was 
detected in all lysates, except in the mock transfected cells (Figure 9). No further 
processing of LAMAN peptides abc and d could be observed for p.C55F and p.R750W 
(Figure 9a and b), and they were not secreted (Figure 9c and d). In contrast, the WT-, 
p.H200L, p.P263L, p.S318L, p.S453F, p.S457E and p.T745R –LAMANs were 
proteolytically processed as judged from the appearance of the 70 kDa peptide abc. The 
40 kDa peptide d was only observed in WT and p.S318L. Mutant p.T745R was not 
secreted into media to any extent as judged from the very low abundance of 120 kDa 
single-chain precursor (Figure 9). The transfected COS-7 cells showed better LAMAN 
proteolytically processing than in BHK cells. The 15 kDa peptide e was observed only 
in wild-type. This result indicates that the mutant LAMAN p.C55F did not home to the 
lysosomes and was probably accumulated in the ER. Whereas, the mutant LAMAN, 
p.H200L, p.P263L, p.S318L, p.S453F, p.V457E and p.T745R were partly transported 
to the lysosomes as judged from appearance of peptide abc. The same pattern of 












































C) COS-7 media 
  
 
D) BHK media 
  
 
Figure 9 Western-blot analyses of mutant human LAMANs 
Ten µg cell lysate and 10µl medium from COS-7 and BHK cells transfected with 
various mutant LAMAN constructs were subject to SDS/PAGE and electroblotted on to 
a PDVF membrane as described in Material and Methods section. The molecular 







Glycosylation of mutant alpha-mannosidases 
The human LAMAN enzyme is N-glycosylated by both high-mannose and complex 
type glycans (Nilssen et al., 1997; Berg et al., 1997 ; Faid et al., 2006, Hansen et al., 
2004). In order to study the type of N-linked glycans on mutant LAMANs, the COS-7 
cell lysates were treated with Endo H and PNGase F and separated by SDS-PAGE. The 
result showed a decrease in molecular weight of  the precursors after treatment PNGase 
F, due to its removal of N-glycans. The 120 kDa precursor and 70 kDa peptide abc of 
mutant LAMANs, p.H200L, p.P263L, p.S318L, p.S453F and p.V457E were partially 
deglycosylated by endo H, indicating that these mutant LAMANs were occupied by 
both high-mannose and complex N-glycans (Figure 10). The presence of complex N-
glycans indicates that these mutant LAMANs have been transported through Golgi. 
The complete reduction of precursor abcde-petides of p.C55F after treatment with Endo 
H, indicates that this peptide contained mainly of high-mannose N-glycans, it had not 
reached the complex glycan-synthesizing enzymes of the trans-Golgi network.  
The precursor of p.T745R  was also endo H sensitive, but the 70 kDa peptide abc was 
partially deglycosylated by endo H, indicating that this abc peptide contain both high-
mannose and complex N-glycans. The untreated protein showed a double band pattern 
could be caused by heterogenous glycosylation, or the antibody could have reacted with 
some LAMAN precursors that the host cells have produced. 
 
A ) COS-7 lysates 
 
Figure 10 Molecular-shift analysis after Endo H and PNGase F treatments 
COS-7 cells were transfected with pcDNA containing wild-type and various mutations, 
the cells were harvested for 48 hours. The lysates were treated with endo H and 
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PNGase F, separately by SDS/PAGE and analysed by Western Blot. The positions of 
the respective LAMAN peptide fragments are indicated on the left. 
 
Intracellular localization of mutant LAMAN 
In order to study the the levels of LAMAN protein expression and intracellular 
distribution, the immunofluorescence studies were carried out in COS-7 cells 
transfected with the pcDNA3.1-LAMAN, the seven mutants, mock, and p.R750W 
constructs. The cells were fixed and stained with anti-LAMAN abc peptide, LAMP-1 
and PDI and examined by immunofluorescence microscopy as described in Materials 
and Methods section. As seen in the figure 11, p.H200L, p.P263L, p.S318L, p.S453F, 
p.V457E and p.T745R  LAMANs were co-localized with the lysosomal marker LAMP-
1 and ER marker PDI, hence indicating that these mutant LAMANs were localized in 
ER and partially sorted to lysosomes similar to wildtype. Whereas, p.C55F and 
p.R550W were only co-localized with PDI, indicating that they were folded abnormally 
and prevented to pass through the ER control system. 
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Figure 11 Immunofluorescence microscopy of LAMAN mutants in transfected 
COS-7 cells. 
Double immunofluorescence staining was performed using antibodies against LAMAN 
abc peptide, LAMP-1 and PDI. Yellow indicates overlap of the LAMAN peptides 
















In my previous project work, I identified 3 novel putative disease causing mutations in 
3 independent mannosidosis patients. The mutations were p.C55F, p.H200L and 
p.V457E. A set of 55 of normal norwegian control subjects were used to screen for 
each of the missense mutations. None of these mutations were identified in the 55 
normal control subjects, confirming that these mutations do not represent frequent 
polymorphisms, suggesting that they could be the disease-causing mutations. 
In the present work, I have further characterized these mutations along with 4 other 
putative disease-causing mutations (see table 2). In order to evaluate their biochemical 
and biological consequences, seven missense mutations were introduced into 
pcDNA3.1 containing wild-type LAMAN and  expressed in transfected COS-7, and 
BHK-21 cells. The results are summarized in table 6. 
 
In vitro expression of LAMAN mutants 
Cell extracts and culture medias were assayed for alpha-mannosidase activity both on 
transfected COS-7 and BHK cells. The enzyme activity varied in two independent 
transfection experiments. The variation in enzyme activity could be due to the 
transfection efficiency or it might have been affected by  the process of harvesting the 
lysates. The COS-7 and BHK cells transfected with the following mutant LAMAN 
constructs expressed activities higher than the background : pcDNA-WT, pcDNA-
H200L, pcDNA-S318L, pcDNA-S453F, pcDNA-V457E and T745R. Alpha-
Mannosidase activity in the mutant plasmids containing p.C55F and p.P263L or 
p.R750W showed no increase over background levels (Figure 8). Mutation p.C55F  
disrupts the disulphid brigde of Cys55-C358 important for enzyme conformation 
(Heikinheimo et al., 2003 and Hansen et al., 2004). Sequence alignment studies with 
alpha-mannosidase sequences from other species (e.g human, cow, rat, pig, mouse and 
Drosophila, see appendix) had shown that these aa residues mutations are conserved 
within the class 2 alpha-mannosidase family indicating that they probably serve 





Intracellular processing of mutant LAMANs 
To study the expression and proteolytic maturation of the mutant enzymes, COS-7 and 
BHK-21 cells were transfected with mutated plasmid constructs. The cell lysates and 
medias were harvested after 48 hours. The result showed that the mutants, p.H200L, 
p.P263L, p.S318L, p.S453F, p.V457E and p.T745R were partly transported to the 
lysosomes as judged from proteolytic processing into the peptides abc and d (see figure 
9) and partly secreted as single chain forms (Figure 9). As proteolytic cleavage of abc 
and d was observed, indicates that processing was taken place in the lysosomes 
(Hansen et al., 2004). Thus, it appeared that these mutant could have an intracellular 
transport similar to wild-type LAMAN. The appearance of 42 kDa peptide d observed 
in COS-7 but not in BHK,  may be the result of a slow proteolysis between peptides abc 
and d in in BHK cells. Further partial processing of peptide abc into peptides a, b, c 
could not be observed in our expression system. Proteolytically processing of peptide 
abc into a, b and c is a late lysosomal processing event (Nilssen et al., 1997). These 
LAMAN-variants  except p.T745R were, like the wild-type, secreted into the medium 
in the 120 kDa precursor form. This may be caused by saturation of the sorting system 
in the trans Golgi network (Hansen et al., 2004) or it could be a fraction LAMAN 
protein that was not disassociated from the Mannose-6-phosphate receptor in the acidic 
environment. The high level of proteolytic processing and secretion correlated with 
residual activity. 
In contrast, other mutants, p.C55F and p.R750W were neither proteolytically processed 
nor secreted as a single-chain form. This result suggests that these mutants did not enter 
the endosomes/lysosomes. They were probably retained or degraded in ER. The result 
could be related to the low of alpha-mannosidase activity of these mutants. The mutant 
p.T745R was proteolytically processed as judged from the appearance of peptides abc 
and d, but the 120 kDa single-chain precursor was not secreted into the extracellular 
environment (Figure 9). The reason could be explained by that p.T745R  enzyme did 
not enter the secretory pathway. Probably, it was completely disassociated from the 
receptor in the acidic environment and transported to the lysosomes. As jugded from 





N-linked glycans  of mutant enzymes 
Glycoproteins are generated in the ER, and N-glycosylation of polypeptides is followed 
by a series of trimming reactions. The correctly folded proteins are further transported 
to the Golgi for additional modifications (Plemper and Wolf 1999). Lysosomal proteins 
are generally modified by addition of the M-6-P marker for targeting to the lysosome. 
Many lysosomal proteins undergo their final proteolytic cleavage in the lysosomes. The 
human LAMAN amino acid sequence contain 11 potential N-glycosylation sites. These 
N-glycosylation sites are occupied by high mannose and complex type N-linked 
(Nilssen et al., 1997). The result of deglycosylation (see figure 10) demonstrated that 
wild-type LAMAN precursor contained both of endo H-sensitive and resistant N-
glycans. The LAMAN mutants , p.H200L, p.S318L, p.S453F and p.V457E precursors 
contained both of endo H sensitive and resistant N-glycans as judged from the partially 
deglycosylation by endo H, suggesting that a small fraction of these mutant proteins 
have reached Golgi network. The intracellular level of the single-chain form had 
decreased and two peptides of 70 and 40 kDa had appeared, corresponding in molecular 
masses to peptides abc and d. The 70 and 40 kDa peptides were partially endo H-
resistant, indicating that  the N-glycans consist of high-mannose and complex type and 
had been transported through the trans-Golgi network, indicating that they followed the 
same route through the trans-Golgi network as the wild-type. The weak intensity of the 
abc peptides of p.H200L, p.S453F and p.V457E as compared to p.P263L and p.S318L 
may due to the fact that only a small fraction of LAMAN is being transported to the 
lysosomes.  
Mutant p.C55F and p.R750W (Hansen et al., 2004) remained as intracellular single-
chain forms and were not secreted. They were endo H and PNGase F sensitive, this was 
probably a form that was retained in the ER (endoplasmic reticulum). They may have 
been folded incorrectly and thus trapped in the ER by the folding control system.  
Especially, the mutant p.T745R precursor showed to be endo H sensitive, but 
surprisingly, the result showed weak proteolytical processing of this mutant into 
peptides abc and d and they were partially endo H-resistant. Since the precursor of this 
mutant contained only endo H sensitive N-glycans type, we may expected that it has 
not reached the complex glycan synthesizing enzymes of the trans-Golgi network. 
Likely a large fraction of the precursor is arrested in ER. This is consistent with a very 
low level of secretion into the media. However, a the small fraction of proteolytically 
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processed peptides of this mutant are occupied by both of high-mannose and complex 
type glycans, suggesting that this fraction follow the same route through Golgi as the 
wild-type enzymes. This mutant is not affected in any of  the N-glycosylation sites. 
 
Intracellular localization of mutant LAMANs 
The intracellular localization of LAMAN polypeptides was studied by 
immunofluorescence microscopy using COS-7 cells transfected with the different 
pcDNA-LAMAN constructs. As seen in Figure 11, the WT-, p.H200L, p.P263L, 
p.S318L, p.S453F, p.V457E and p.T745R-LAMANs were co-localized with the 
lysosomal marker LAMP-1. This indicate that these mutants were processed and 
targeted to the lysosomes similar to that of wild-type LAMAN, therefore confirming 
the normal sorting of these mutants.  
In contrast, the p.C55F- and p.R750W –LAMANs were co-localized with the ER 
marker, but not with LAMP-1. This demonstrated that these mutants were expressed at 
significant levels as evidenced by immunofluorescence studies. Probably, these mutants 
folded abnormally and quickly degraded in ER. Such misfolding and ER retention were 
consistent with the fact that the precursor contained only high-mannose N-glycans and 
did not secrete the single-chain precursor. It also possible that a very small fraction of 
p.C55F escaped from the quality control system in the ER and were transported into the 
lysosomes. The method is not sensitive enough for detection a very small fraction of 
protein. The results suggest that p.H200L, p.P263L, p.S318L, p.S453F, p.V457E and 
p.T745R-LAMANs were partially processed, transported and localized to the 
lysosomes, but p.C55F and p.R750W were misfolded and arrested in ER. 
 
Alpha-mannosidosis-causing mutations can be divided into two groups 
according to their effect on intracellular processing, localization an 
enzyme activity of LAMAN 
Taken together, the results from enzyme activity, western blot, deglycosylation, as well 
as the results from studies of immunofluorescence (Table 6), we divided the mutants 
into two main groups according to their intracellular routes: 1) Lysosomal sorting and 
secrection and 2) Transport arrest in the endoplasmic reticulum. p.C55F and p.R750W 
mutations resulted in inactive LAMAN-variants that probably did not pass the folding 
control system and were thus arrested in the ER in a one-chain precursor form. The 
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observed precursor polypeptides were retained in the ER, likely due to incorrect 
folding. These mutants could be categorized into group 2 (Hansen et al., 2004). 
The group 1: mutants H200L, p.P263L, p.S318L, p.S453F, p.V457E and p.T745R 
resulted in LAMAN variants that were proteolytically processed and targeted to the 
lysosomes and resulted either in no residudal activity or residual activity. A small 
fraction of enzymes could have folded sufficiently to pass the ER control system. The 
mutant p.H200L were previously reported and predicted to be an active site mutations 
(Sharagli et al., 2005). The distortion of the active site in this mutant did not affect 
intracellular sorting and stability of the mutant enzyme in this study. The p.P263L 
variant displayed lysosomal sorting, but had decreased activity towards the artificial 
substrate p-nitrophenyl- alpha-mannopyranoside. 
 
We performed the experiments in an artificial system. We forced the cells to massively 
express mutant LAMAN enzymes, and the artificial enzyme substrate was used in order 
to study their activity towards the more complex natural oligomannosidic substrates. 
Over-expression of enzymes could result in saturation of the ER system such that a 
fraction of enzyme could escape the folding control system of the ER. It is conceivable 
that these mutants could have decreased in vivo stability, or zero activity towards the 
more complex natural substrates in the alpha-mannosidosis patients. Furthermore, 
residual activity may be caused by other acidic alpha-mannosidases being 
misinterpreted as residual activity (Nilssen et al., 1997). At present, we do not know if 
the residual activity we observed for LAMANs carrying human p.H200L, p.S318L, 
p.S453F, p.V457E and p.T745R muations could reflect the in vivo situation. LAMAN 
enzymes, even though containing residual activity upon testing at appropiate pH, may 





























































































































































































































































































































































































































































































































































































































































































































































































































































Missense mutation p.C55F resulted in no ezyme activity in transfected cells. This 
missense-mutation probably resulted in misfolding and ER-retention. This was 
consistent with non lysosomal localization in transfected cells. The mutant is most 
probably disease-associated mutation. The six other mutant variants resulted either in 
no significant residual or low activity, but they were parially proteolytically processed 
and partially sorted to the lysosomes. However, in this study we used an artificial 
expression system, the tranfected cells were forced to producing these mutant 
LAMANs  in large quantities scales. This might not reflect in vivo situation, where 
mutant enzymes may have lower stability and affinity toward to the more complex 
natural substrate in tissues, compared to in the overexpressing cells. Finally, I am aware 
of the possibility that there could be another mutations localized in the non-codings 


















Recently, only p.H200L was successfully modelled into the three-dimensional structure 
of bovine LAMAN (Sbaragli et al., 2005). A further goal is to the determine the 3-D 
structure of the mutant LAMANs caused by p.P263L, p.S318L, p.S453F, p.S457E and 
p.T745R. The information obtained from the 3-D structure and from this work together 
will contribute to increase understanding of the mutant LAMANs, and also extend the 
understanding of the biochemical and cellular consequences of these suggested disease-
causing sequence variants. Future work should also involve more specific experiments, 























Table A  Primer used for contruction of mutants  
 Mutation          
cDNA Primer  Direction sequence 
level protein level 
      
 
c.788C>T p.P263L  Forward  5’-CCCAATGGTTACAACCTGCCAAGGAATCTG-3’ 
    Reverse  5’-GCACAGATTCCTTGGCAGGTTGTAACCATT-3’ 
 
c.909+ p.S318L  Forward  5’-GATGACCATGGGCTTGGACTTCCAATATG-3’ 
731del6272   Reverse  5’-CATATTGGAAGTCCAAGCCCATGGTCATC-3’ 
(IVS6+731del6272) 
 
c.1358C>T p.S453F  Forward  5’-GTCAGCGGCACCTTCCGCCAGCACGTG-3’ 
    Reverse  5’-CACGTGCTGGCGGAAGGTGCCGCTGAC-3’ 
  
 
c.2234C>G p.T745R Forward  5-GGGACGCTTCTACAGAGACAGCAATGGC-3’ 




















Appendix ! Sequence alignment 
 
Drosophila         ----------------------MSAKTSVWLVFFCALGCLIHDADLRSIQPKASQCGYQS 38 
Tribolium          ----------------------MFRRTLVPAWIFA--GVCFHLCATAAIKS-ATQCGYQA 35 
Cow                MVGDARPSGVRAGG-CRGAVGSRTSSRALRPPLPPLSSLFVLFLAAPC----AWAAGYKT 55 
Cat                MGADARPLGVRAGGGGRGAARPGTSSRALPPPLPPLS-FLLLLLAAPG----ARAAGYET 55 
Human              MGAYARASGVCARG-CLDSAGPWTMSRALRPPLPPLC-FFLLLLAAAG----ARAGGYET 54 
Guinea  pig        MGASVLPLGLGAGD-CQSSSGRRMSACLPR---TALSFLLSLLLATPG----ARAAGYET 52 
Xenopus            MER------------------------------VELLLLPLLLLGAAGRLKQAEGCGEQS 30 
Nematostella       -------------------------MGVLGKKCDILAVLYLTCFISSS----LCFQCAEK 31 
Ciona              ---------------------------MLG----LFIVILASCCTASA----DVSCGYHS 25 
Acyrthosiphon      -----MVVLLTGMAVRTFDRSRVVRFRFAAAVCVAVFALLARTTAADAAESSSSGCAPKS 55 
                                                                             .  
 
Drosophila         CHPTKPNMLNVHLVAHTHDDVGWLKTVDQYYYGSETKIQKAGVQYIIDSVVEALLRDPEK 98 
Tribolium          CNPIKDGFINVHLVPHTHDDVGWLKTVDQYFYGANNSIQNAGVQYIIDSVIDELKKDPKR 95 
Cow                CPKVKPDMLNVHLVPHTHDDVGWLKTVDQYFYGIYNNIQPAGVQYILDSVISSLLANPTR 115 
Cat                CPMVHPDMLNVHLVAHTHDDVGWLKTVDQYFYGIHNDVQHAGVQYILDSVISSLLVEPTR 115 
Human              CPTVQPNMLNVHLLPHTHDDVGWLKTVDQYFYGIKNDIQHAGVQYILDSVISALLADPTR 114 
Guinea  pig        CPIVQPGMLNVHLVAHTHDDVGWLKTVDQYYWGIHNDLQQAGVQYILDSVISALLAEPTR 112 
Xenopus            CPQAPDGFLNVHLIPHTHNDVGWLKTVDQYYYGAHNDIQHAGVQYILDSVVSQLLHDPSK 90 
Nematostella       GAGKDAEKLQIHIVPHTHDDVGWLKTVDEYFYGANNSIQHAGVQYILDSVIPALNEDPNK 91 
Ciona              CNLGEAEKLNVHLVPHTHDDVGWLKTVDQYYYGSNSSIVIAGVQYILDSVIPQLLSDPSK 85 
Acyrthosiphon      CNAIDPNKLNVHLIAHTHDDVGWLKTVDQYYYGSNKAHAPYGVQYIMDSVVSELLKNKNR 115 
                           :::*::.***:*********:*::*  .     *****:***:  *  :  : 
 
Drosophila         RFIYVESAFFFKWWKEQKPKVQEAVKMLVEQGRLEFIGGAWSMNDEATTHYQSVIDQFSW 158 
Tribolium          KFIYVETAYFWKWWIHQHDFVKHQVKTYVNNGQLEFIGGAWTMNDEATTHYQSIIDQFTW 155 
Cow                RFIYVEIAFFSRWWRQQTNATQKIVRELVRQGRLEFANGGWVMNDEATTHYGAIIDQMTL 175 
Cat                RFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIIDQMTL 175 
Human              RFIYVEIAFFSRWWHQQTNATQEVVRDLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTL 174 
Guinea  pig        RFVYVEMAFFSRWWHQQTNETQEVVRRLVRQGRLEFANGGWVMNDEAATHYGAIVDQMTL 172 
Xenopus            RFIYVESAFFWRWWKQQDELVRRDVTRLVEEGRLEFINGGWSMNDEAATHYSSIIDQMTL 150 
Nematostella       RFIYVEIAFFKRWWDQQNVEMQEIVKKLVLQKRLEFINGGWCMNDEAATHYNAIIDQMTV 151 
Ciona              RFIYVEIAFFSRWWEEQNDAMKENVKQLVQEGRLEFILGGWCMNDEASTHYNAIIDQMTH 145 
Acyrthosiphon      KFVFVETAFLWRWWEEQDEWNRNSLKTLVHEGRLQLLHGGWVMSDEAVPHYSTLIDQMTL 175 
                   :*::** *:: :** .*    :. :   * : :*::  *.* *.*** .** :::**::  
 
Drosophila         GLRLLNDTFGECGRPRVGWQIDPFGHSREMASMFAQMGFDGMFFGRLDYQDKDERLMTKN 218 
Tribolium          GLRKLNDTFGDCGRPKIGWQIDPFGHSREMASIFAQLGFDGLLLGRIDYEDKDKRFESKT 215 
Cow                RLRFLEETFGSDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKKVRKKTLQ 235 
Cat                GLRFLEDTFGKDGRPRVAWHIDPFGHSREQASLFAQMGFDGLFFGRLDYQDKRVREENLG 235 
Human              GLRFLEDTFGNDGRPRVAWHIDPFGHSREQASLFAQMGFDGFFFGRLDYQDKWVRMQKLE 234 
Guinea  pig        GLRFLEDTFGSDGRPRVAWHIDPFGHSREQASLFAQMGFDGVFFGRIDYQDKLVRKKRRE 232 
Xenopus            GLQFLKSTFGDCGRPRVAWHIDPFGHSREQALLFAQMGYDGFFFGRLDYQDKANREKTKQ 210 
Nematostella       GLKFIEETFGSDARPRIAWHIDPFGHSNEQASLFAQMSFDGFFFGRIDYDDKTLRLKQQR 211 
Ciona              GLRYLNDTFGACARPRVAWQIDPFGHSREQASLFAQMGFDGLFFGRLDYEDKENREKIRN 205 
Acyrthosiphon      GLKFLNETFGECARPRVAWQIDPFGHSSEVAAEFAEMGFDGLVLGRIDHEDLALRKQQKT 235 
                    *: ::.***  .**::.*:******* * *  **::.:**..:**:*::*   *      
 
Drosophila         AEMIWHGSAN--LGEEADLFSGALYNNYQAPDGFCFDILCNDAPIIDGKHSPDNNVKERI 276 
Tribolium          PEMIWKGSDN--L--DADIFTGVMYNTYAPPKGFCFDIMCDDEPLVDDKKSPLYNIERKV 271 
Cow                MEQVWRASTS-LKPPTADLFTSVLPNMYNPPEGLCWDMLCADKPVVEDTRSPEYNAKELV 294 
Cat                LEQVWRASAS-LKPPAADLFTSVLPNIYNPPEKLCWDTLCADKPFVEDRRSPEYNAEELV 294 
Human              MEQVWRASTS-LKPPTADLFTGVLPNGYNPPRNLCWDVLCVDQPLVEDPRSPEYNAKELV 293 
Guinea  pig        MELVWRASAS-LKAPAADLFTGVLPNNYGPPEGLCWDVLCADPPVVDDPRSPEYNAKKLV 291 
Xenopus            MEMLWRASDD-ISPPYADLFTGVLPNGYNPPDGFCWDQLCDDTPIIDDPSVEDYNADVIV 269 
Nematostella       MEMVWRGSKSGNLGKNSDIFTGVLYNGYNPPPGFCFDQFCSDQPIQDDPRLYDENVKQRV 271 
Ciona              MEEIWRGSQS-LTSPHADLFTGVDENGYNPPDGFCFDAFCRDQPIMDNPALEDYNVEEKV 264 
Acyrthosiphon      MEMVWRPDVN--MGQGGELFTSVLYNLYVAPEGFCFDAFCNDDPILDNPKLHGYNVNAKV 293 









Drosophila         DTFLDFAKTQSQYYRTNNIIVTMGGDFTYQAAQVYYKNLDKLIRYGNERQ-ANGSNINLL 335 
Tribolium          DDFFAYLDNVTKAYTTSNVIITMGEDFNYQNAHTWFKNLDKLIYYANQRQ-INGSKYNLL 330 
Cow                RYFLKLATDQGKLYRTKHTVMTMGSDFQYENANTWFKNLDKLIQLVNAQQRANGIRVNVL 354 
Cat                NYFLQLATAQGQHFRTNHTIMTMGSDFQYENANMWFRNLDRLIQLVNAQQQANGSRVNVL 354 
Human              DYFLNVATAQGRYYRTNHTVMTMGSDFQYENANMWFKNLDKLIRLVNAQQ-AKGSSVHVL 352 
Guinea  pig        SYFLQLATAQGRYYRTNHTVMTMGSDFQYENANTWFKNLDKLIQLVNMQQ-ANGSRVHVL 350 
Xenopus            QKFLKAATQQAQKYLSSHIVMTMGSDFQYENAIMWFKNMDRLIKNVNMQQ-INGSKVNVF 328 
Nematostella       EEFIKLACEQGSQYKSNNIMMTMGSDFMYENANLWYKNLDKLIAHVNQDS----R-VRAF 326 
Ciona              DKFVAAALKQANHFQTNHIMMTMGSDFEYSNSNVWYKNLDKLIKYVNAAD----KNMTLF 320 
Acyrthosiphon      ENFANHVKRYASAFKTNNIMITMGGDFSYSVASSWFRNMDKLIKHVNILK----PDLNVL 349 
                     *          : :.: ::*** ** *. :  :::*:*:**   *  .         : 
 
Drosophila         YSTPSCYLKSLHDA--GITWPTK-SDDFFPYASDPHAYWTGYFTSRPTLKRFERDGNHFL 392 
Tribolium          YSTPSCYTKAVHDS--NQKFVSK-TDDFFPYSSDGNSFWTGYFTSRPTLKRFERQGNNFL 387 
Cow                YSTPACYLWELNKA--NLSWSVK-KDDFFPYADGPYMFWTGYFSSRPALKRYERLSYNFL 411 
Cat                YSTPACYLWELNKA--NLTWSVK-QDDFFPYADGPHQFWSGYFSSRPALKRYERLSYNFL 411 
Human              YSTPACYLWELNKA--NLTWSVK-HDDFFPYADGPHQFWTGYFSSRPALKRYERLSYNFL 409 
Guinea  pig        YSTPACYLWELNKA--NLTWPVK-EDDFFPYADGPHMFWTGYFSSRPALKRYERLSYNFL 407 
Xenopus            YSTPSCYLQSLHRA--NLTWPMK-MDDFFPYADGPHMFWTGYFTSRPAFKGYERLSNNFL 385 
Nematostella       YSTPTTYLEALHAA--NLTWGLK-TDDFFPYADCPHCYWTGYFTSRPALKRYSRLNNNLL 383 
Ciona              YSTPSCYLYALNHA--NVMWNIK-KDDFFPYADAPHQYWTGYFTSRPGLKGYVRESNKYL 377 
Acyrthosiphon      YSTPECYLSALQMSSKNVTWPLKDSDDFFPYAHDEHSYWTGYFTSRSNLKYMICKANNLL 409 
                   ****  *   :: :  .  :  *  ******:     :*:***:**. :*       : * 
 
Drosophila         QVCKQLSALAPKKPEEFDP---HLTFMR---ETLGIMQHHDAITGTEKEKVALDYAKRMS 446 
Tribolium          QVCKQLYALVDLGPEDWV----DLNALR---EAMGVMQHHDAITGTEKQHVAEDYARILQ 440 
Cow                QVCNQLEALAGPAANVGPYGSGDSAPLN---EAMAVLQHHDAVSGTSRQHVANDYARQLS 468 
Cat                QVCNQLEALAGPAANVGPYGSGDSAPLN---QAMAVLQHHDAVSGTSKQHVADDYARQLA 468 
Human              QVCNQLEALVGLAANVGPYGSGDSAPLN---EAMAVLQHHDAVSGTSRQHVANDYARQLA 466 
Guinea  pig        QVCNQLEAQVGPAANVGPYGHGDSSPLN---QAMAVLQHHDAVSGTSKQHVADDYARQLA 464 
Xenopus            QVCNQMEALSGLEARNGPYGQSSSTVMR---RAMGVAQHHDAVTGTAKQHVNNDYSLRLS 442 
Nematostella       QACKQLEVLN---GPAQSGSPSSDLLR----RALAVAQHHDAVSGTSKQHVADDYAKRLA 436 
Ciona              QVCNQLETFMHFKSTSHKLTSSSKVLISFPGDAMGVAQHHDAVSGTSKQHVANDYAKRLY 437 
Acyrthosiphon      QAVKQIGSILGGELNEHVQTLAIAVAQS---------QHHDAITGTEKQHVSDDYAQYLD 460 
                   *. :*:                               *****::** :::*  **:  :  
 
Drosophila         VAFRACGATTRNALNQLTVQSKDNVKDTSAKYVFEFKTCALLNITSCPVSEANDRFALTL 506 
Tribolium          GGIDECQFIVNTALSKIITGENSTGPDPGPK--FPINTCWLTNTSSCPFSEDQDNFLVTV 498 
Cow                EGWRPCEVLMSNALAHLS-----GLKE-------DFAFCRKLNISICPLTQTAERFQVIV 516 
Cat                AGWDPCEVLLSNALARLS-----GSKE-------DFTYCRNLNVSVCPLSQTAKNFQVTI 516 
Human              AGWGPCEVLLSNALARLR-----GFKD-------HFTFCQQLNISICPLSQTAARFQVIV 514 
Guinea             AGWGPCEVLLSNALAKLS-----GSKE-------TFLFCRDLNISICPFSQTSERFQVLV 512 
Xenopus            EGWDSCQVVISNSLSSLT-----GTKE-------NFAFCNLLNISVCHVTETANNFKVYL 490 
Nematostella       IGAADCQALMSNVIGKKSIKSKGNAPP-------VFSSCNLLNVSSCPSTEDSKSFVVNA 489 
Ciona              EGREECNKVISTALTGN------NEQL-------IF--CDYLNITLCDLTQSSNQFVVMV 482 
Acyrthosiphon      EGIGESQKVLTAAYRKWFG---KDFPE--------QQYCKMLNISECDVSENNSKFVITL 509 
                    .   .                                *   * : *  ::    * :   
 
Drosophila         YNPLAHTVNEYVRIPVPYSNYRIIDNKGVTLES----QAVPIPQVLIDIKHRNS----TA 558 
Tribolium          YNPLSRPVTKYVRLPVIGEAYNVKCPQGKELLT----QLIPIPDAVKNMPGRVS----KA 550 
Cow                YNPLGRKVDWMVRLPVSKHVYLVKDPGGKIVPS----DVVTIPSSDSQ------------ 560 
Cat                YNPLGRKIDWMVRLPVSKHGFVVRDPNGTVVPS----DVVILPSSDGQ------------ 560 
Human              YNPLGRKVNWMVRLPVSEGVFVVKDPNGRTVPS----DVVIFPSSDSQAHPP-------- 562 
Guinea  pig        YNPLGRKVDRMVRLPVRKGLFLIKDPGNNTVPS----TVVELTSSGNP------------ 556 
Xenopus            YNPLGRSVTWTVRLPVNGHAYKVIGPNDETVPS----EVVDVSDFTKALRFQQ----GGA 542 
Nematostella       YNPIARDITSYIRVPVNLP-MSVYNPQGAAIKS----QLLPISQETMTLRRMQKLSASNS 544 
Ciona              YNPLARGVSKYLRIPVNCDDHYVYVVDDLATSTRLTVQLVPVSEATLSVRRNR----GSA 538 
Acyrthosiphon      YNPLSRAVTTPVRIPVKYADYKVTGPNGANVPY----ELVFLPGQIFRLGGRTS----NA 561 










Drosophila         KYEIVFLATNIPALGYRTYYVEKLDSTEGNTRSK--ALPKRTSSVTVIGNSHIQLGFDTN 616 
Tribolium          TVELIFEAPFVPPLGFKTFTVSKKTGNE----------VLKAEKITKIADGEVGFTLDPN 600 
Cow                --ELLFSAL-VPAVGFSIYSVSQMPNQRP---------QKSWSRDLVIQNEYLRARFDPN 608 
Cat                --ELLFPAS-VPALGFSIYSVSQVPGQRPHAHKPQPRSQRPWSRVLAIQNEHIRARFDPD 617 
Human              --ELLFSAS-LPALGFSTYSVAQVPRWKPQARAPQPIPRRSWSPALTIENEHIRATFDPD 619 
Guinea  pig        --ELLFPAL-VPALGFSVYSVTRVSDQNPQTRSQHSRPQKYSSPVLSIKNEYLRASFHPD 613 
Xenopus            ERELIFQGQ-IPAVGFSSFTVGKLSLPDRFVIK----GKRGKKQPDKIQNQYYRVDFDPE 597 
Nematostella       KYELIFKVK-LPPLGFASYFVNTSKTSSKMYGKS-FAVDPST----VIQNEFIKLEFSRD 598 
Ciona              NCELVFLAK-LPALGHNTFQVTKHKTSKTVSLLK-TKVEKVINQDVTITNEFYKVKFDGN 596 
Acyrthosiphon      THELLFIASEVSPLGLVNYHVERINEPEPPPRP----MPYNSTEDVTIDNGKLKIGFNGI 617 
                     *::*    :..:*   : *                          * :      :    
 
Drosophila         -GFLSEVT--ADGLTRLVSQEFLFYEGAVGNNAEFLNRSSGAYIFRPNENK-IHFATD-- 670 
Tribolium          SGLLKTVI--LNGKTVDVNQEFLYYEGFVGDNEEPKNRSSGAYIFRPIPGKDPVVVAD-- 656 
Cow                TGLLMELENLEQNLLLPVRQAFYWYNASTGNNLS--SQASGAYIFRPNQNKPLFVSHW-- 664 
Cat                TGLLVEMENLDQNLLLPVRQAFYWYNASVGNNLS--TQVSGAYIFRPNQEKPLMVSHW-- 673 
Human              TGLLMEIMNMNQQLLLPVRQTFFWYNASIGDNES--DQASGAYIFRPNQQKPLPVSRW-- 675 
Guinea  pig        TGLLSMIEVLDRKLTLPVNQAFFWYNASVGDKRS--SQASGAYIFRPSQQWPFPVSHL-- 669 
Xenopus            TGLISGIHNLEKKISLPLKQSFYWYNASVGNEES--SQPSGAYIFRPNNSDSVPVSQH-- 653 
Nematostella       TGRLTSMTDLVSEVTTQVDQQFLWYNASVDQG-----QPSGAYIFRPNTSSTTPVNAGGK 653 
Ciona              TGLMASIENIASGITVPVKQDMLWYNASMGNDES--KQQSGAYIFRPNVSTPFQLIIG-- 652 
Acyrthosiphon      SGLVQWIE--KNGTRHQLQQNFFFYESMKGYNFNADNRASGAYIFRPTKSQPTAISEK-- 673 
                    * :  :          : * : :*:.  .       : ********       .      
 
Drosophila         QVEIEVYKGDLVHEVHQKFNDWISQVVRVYNKDSYAEFEWLVGPIPIDDGIGKEVITRFN 730 
Tribolium          KVDYKIFRGNLVSEVQQVFNEWITQTIRVYRTESYIEFDWIVGPIPDTDANGKEIITRFT 716 
Cow                -AQTHLVKASLVQEVHQNFSAWCSQVVRLYPRQRHLELEWTVGPIPVGDGWGKEVISRFD 723 
Cat                -AQTRLVKTPLVQEVHQNFSAWCSQVVRLYRGQRHLELEWTVGPIPVGDGWGKEIISRFD 732 
Human              -AQIHLVKTPLVQEVHQNFSAWCSQVVRLYPGQRHLELEWSVGPIPVGDTWGKEVISRFD 734 
Guinea  pig        -ARTRLVKTALVQEVHQNFTAWCSQVVRLYSGQRHLELEWTVGPIPVGDKWGKEIISRFD 728 
Xenopus            -VRSYLVQNSLVQEVHQNFSSWCSQVVRLYRDQRYIELEWTVGPVPIGDEWGKEVISLIE 712 
Nematostella       ATFTVYQG-PLVQEVRQVFSPYVSQVVRLYYGQKHAEFEYTVGPIP--DDLGREVITRFD 710 
Ciona              CVFNIQGSNLLVQEVYQKFSDWVWQVIRLYAGKKQIEVEWTVGPIPVQDKWGKEIISRYE 712 
Acyrthosiphon      -INLTIYRGKNVHEVHQSFSSWLSQVVRIYDQQESIEFEWLVGPIPIMEWIGKEVITKYA 732 
                              * ** * *. :  *.:*:*  .   *.:: ***:*  :  *:*:*:    
 
Drosophila         SDIASDGIFRTDSNGREMIKRKINHRDTWSVKINEAVAGNYYPITTKIDVEDDT--ARMA 788 
Tribolium          TPLNTKSTFYTDSNGREMLKRVRNARPTWTLTLEEPVSGNYYPVTSKIVLVDESQDLELA 776 
Cow                TALATRGLFYTDSNGREILERRRNYRPTWKLNQTEPVAGNYYPVNSRIYITDGN--MQLT 781 
Cat                TVLETKGLFYTDSNGREILERRRDYRPTWKLNQTETVAGNYYPVNSRIYIRDGN--MQLT 790 
Human              TPLETKGRFYTDSNGREILERRRDYRPTWKLNQTEPVAGNYYPVNTRIYITDGN--MQLT 792 
Guinea  pig        TPLETGGVFFTDSNGREVLERRRDYRPSWKLNQTEPVAGNYYPVNSRIYITDGK--MQLT 786 
Xenopus            TNLKTDGVFYTDSNGRQILKRRRDSRETWKLNQTEPIAGNYYPVNSRIYIKGKN--TQVT 770 
Nematostella       SDIKSNKVFYTDANGREMQLRTRDFRPTWKLNNTEPVAGNYYPVNSRIFVKDSN--RQLT 768 
Ciona              TNLETNGYFYTDSNGREILERRKDYRPTWHLNQSESVAGNYYPVNSRIYIHDNQ--VQLT 770 
Acyrthosiphon      TKIASNGTFYTDSNGRRWMQRKRNQRSSWNLTLTEPVSSNYYPITSSIAIRDAI--HQAT 790 
                   : : :   * **:***.   *  : * :* :.  *.::.****:.: * : .     . : 
 
Drosophila         ILTDRAQGGSSLKDGSLELMVHRRLLKDDAFGVGEALNET-EYGDGLIARGKHHLFFGKS 847 
Tribolium          VLTDRAQGGTSLQDGQLELMVHRNCLHDDAFGVAEALNET-AFGKGLVARGSHFLTLGPH 835 
Cow                VLTDRSQGGSSLRDGSLELMVHRRLLKDDARGVGEPLNKE---GSGLWVRGRHLVLLDKK 838 
Cat                VLTDRSQGGSSLRDGSMELMVHRRLLKDDGRGVGEALLED---GLGRWVRGRHLVLLDKV 847 
Human              VLTDRSQGGSSLRDGSLELMVHRRLLKDDGRGVSEPLMEN---GSGAWVRGRHLVLLDTA 849 
Guinea pig         VLTDRSQGGSSMSDGSLELMVHRRLLKDDGRGVGEALQEP---GSGGWVRGRHLLLLDTA 843 
Xenopus            VLTDRSQGGSSIRDGSLELMVHRRLLRDDYRGVGEPLLENGLLGEGIVVRGRHLLLLDHA 830 
Nematostella       LLTDRSLGGSSLKDGSVELMLHRRLLVDDKRGVDEPLNESGISGKGLIVRGKVNVVLAPP 828 
Ciona              VLNDRSQGGSSLSTGQLELMIHRRLLGEDSKGVGEALNETGQFGDGLISRGKHWLLLDTV 830 
Acyrthosiphon      VITDRPQGGTSIEDGTLELMLHRRLLYDDSQGVSEPLDEN-QYGEGMVTRGKHILHFNEL 849 











Drosophila         TDREG-VSLKGIERLTQLEKLLPTWKFFSNMEDYSADEWQTAFTNIFSGISLVLPKPVHL 906 
Tribolium          FKKTGNVSTAALERDIAQRKVLDSWVFIS------APYNDSKYIKEFSGLKRALPANVQI 889 
Cow                ETAAARHRLQAEMEVLAPQVVLAQGGGARYR-------LEKAPRTQFSGLRRELPPSVRL 891 
Cat                RTAATGHRLQAEKEVLTPQVVLAPGGGAPYH-------LKVAPRKQFSGLRRELPPSVHL 900 
Human              QAAAAGHRLLAEQEVLAPQVVLAPGGGAAYN-------LGAPPRTQFSGLRRDLPPSVHL 902 
Guinea             REAAAEHRLLAEKELLAPQLVLAPGQGPSYHH----DHHEAVPRKQFSGLRRQLPPSVRL 899 
Xenopus            DEAADTHRTLALQQYMSPQVVLSSGDGIPYS-------QSGTPKRKFSALNGELPQNGHL 883 
Nematostella       ATSAATHRELGEQMMLEPIVSFAQNPSTVEK-------WLAKYNSLYTGVARQLPSNVHM 881 
Ciona              TSSAKQHRLLAEEIYMSPLVAFQHH---------------APSTTHESHVTSPLPPNIHL 875 
Acyrthosiphon      DKAAKAHRLSALHTAMQPVVTLAPTHMGSNE-------WVSKFSATHKLLNNSLPLNIHL 902 
                             .          :                         . :   **   :: 
 
Drosophila         LTLEPWHENQLLVRFEHIMENGEDAS--YSQPVQFNVKNVLSAFDVEGIRETTLDGNAWL 964 
Tribolium          LTLEPWKGFSFLLRLEHVLEKGEDAD--LSQPAIVNLQNLFTPFEIKSIRETTLGANQWL 947 
Cow                LTLARWGPETLLLRLEHQFAVGEDSGRNLSSPVTLDLTNLFSAFTITNLRETTLAANQLL 951 
Cat                LTLARWDQKTLLLRLEHQFAVGEDSG-NLSSPVTLDLTDLFSAFTITYLQETTLVANQLR 959 
Human              LTLASWGPEMVLLRLEHQFAVGEDSGRNLSAPVTLNLRDLFSTFTITRLQETTLVANQ-R 961 
Guinea  pig        LTLARWGPDTLLLRLEHQFALGEDSSRNLSLPVTLDLQDLFSTFTITRLQETTLAANQLR 959 
Xenopus            LTFAMHAADKILLRLEHPFQS--QESKNNSQPITINLNTLFSSVSLSNFEETTLGANMEK 941 
Nematostella       LTLETSNQY-ALIRLEHQFAD-EDSK--LSMPVNVSLQGLFTDLEVSKVEELNLAANQLL 937 
Ciona              LTLSTTTDGGYIVRVEHQFEKNEDST--LSKPATVSLKNLLTDFHVSSCEELLLGGNAFK 933 
Acyrthosiphon      LTLEHWRKDQVLLRIEHIFEKDEDRF--LSLPETINLQQLFSQLEVLEYKELTLSANLAK 960 
                   **:        ::*.** :    :     * *  ..:  ::: . :   .*  * .*    
 
Drosophila         DESRRLQFAPDPEEAAFNTYATFSQPAESVHLLSAEKPMLGVKYADEALPAGQLGAESNR 1024 
Tribolium          EKNERLEFEAK---------DLFRKNE----------------------------KRATL 970 
Cow                AYASRLQWTTDTGP-------------------------------------------TPH 968 
Cat                ASASRLKWTPNTGP-------------------------------------------TPL 976 
Human              EAASRLKWTTNTGP-------------------------------------------TPH 978 
Guinea  pig        ASASRLKWTTEIDP-------------------------------------------ISR 976 
Xenopus            SRLKRLQWRTRTGSPL----------------------------------------QMDS 961 
Nematostella       KDKHPMQWNIKSVRKSRVRVSGSAKQPS---------LRLANTPVELRPMQIRTFKATLR 988 
Ciona              QDVTRLNWETTEKLKFAPGIDSVSN-------------------------FEKPYDVTNG 968 
Acyrthosiphon      ADLDRYRWNYSDKP------------------------------------------QRPE 978 
                         .:                                                     
 
Drosophila         IRRETETRQEKKDEGRSSKSTEGPYNSFKSDSSNQEYIIELSPMEIRTFIVYLTPA---- 1080 
Tribolium          IR------------------------------ALDDYQITLNPMQIRTFVIEIEKN---- 996 
Cow                PSP----------------------------SRPVSATITLQPMEIRTFLASVQWEEDG- 999 
Cat                PSP----------------------------SRLDPATITLQPMEIRTFLASVQWEEHG- 1007 
Human              QTP----------------------------YQLDPANITLEPMEIRTFLASVQWKEVDG 1010 
Guinea pig         PAV----------------------------PRLDPSSITLQPMEIRTFVASVQWEENS- 1007 
Xenopus            PRA----------------------------PVVDPSNITLSPMEIRTFLANVRYKAALH 993 
Nematostella       MKK----------------------------KSKDSVQMTKIRKAKRVYRLLTSRNG--- 1017 
Ciona              LR-----------------------------QQLDSCDVTLEPMQIRTFLIK-------- 991 
Acyrthosiphon      LN-------------------------------APLPDNLLTPMAIKTYLLTVKPR---- 1003 
  
Figure B : Sequence comparison of LAMAN proteins from different species. The 
sequennces were aligned using the ClustalW 2.0.10 . The amino acid one-letter code is 
used. The human LAMAN amino acid sequence is shaded with light blue colour. The 
conserved residues of LAMAN sequences which had mutated and were identified in 
patients in previous work are indicated by green colour shades. "*" means that the residues 
are identical in all sequences in the alignment. ":" means that conserved substitutions have 
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